Form 8-K - Current report:
SEC Accession No. 0001213900-25-107821
Filing Date
2025-11-10
Accepted
2025-11-10 06:31:01
Documents
15
Period of Report
2025-11-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0264736-8k_nektar.htm   iXBRL 8-K 30713
2 PRESS RELEASE TITLED "NEW DATA FROM REZOLVE-AD STUDY OF REZPEGALDESLEUKIN PRESEN ea026473601ex99-1_nektar.htm EX-99.1 29818
6 GRAPHIC ex99-1_001.jpg GRAPHIC 3555
7 GRAPHIC ex99-1_002.jpg GRAPHIC 978
  Complete submission text file 0001213900-25-107821.txt   241539

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20251108.xsd EX-101.SCH 3008
4 XBRL LABEL FILE nktr-20251108_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE nktr-20251108_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0264736-8k_nektar_htm.xml XML 3565
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 251464230
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)